Commonly observed aberrations in epidermal growth factor receptor (EGFR) signaling have
led to the development of EGFR-targeted therapies for various cancers, including non–small …

Objectives Although the majority of epidermal growth factor receptor (EGFR)-mutant non-
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF
receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular …

Conventional chemotherapeutic regimens have limited impact against most solid tumors
and deal with significant toxicity. Over the last 10 years, novel anticancer treatments …

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …

Within the past 2 years, epidermal growth factor receptor (EGFR) inhibitors have moved from
experimental agents to approved drugs for the management of advanced non–small cell …

The principle of preferentially selecting patients most likely to benefit from therapy according
to their genetic profile has led to substantial clinical benefit in some tumour types, and has …

Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of
non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often …